Annual report pursuant to Section 13 and 15(d)

Revenue - Revenue from contracts with customers (Details)

v3.10.0.1
Revenue - Revenue from contracts with customers (Details)
1 Months Ended 12 Months Ended
Jan. 01, 2018
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
item
contract
Dec. 31, 2017
USD ($)
customer
Dec. 31, 2016
USD ($)
Dec. 31, 2018
customer
Dec. 31, 2018
USD ($)
Disaggregation of revenue              
Revenue     $ 59,505,000 $ 37,833,000 $ 14,198,000    
Change in contract with customer, liability              
Deferred revenue $ 30,090,000           $ 0
Revenue recognized in the period     3,089,000        
Changes in variable consideration     (10,396,000)        
Changes in percentage of completion     5,027,000        
Contract assets, liability and receivables              
Remaining performance obligation             $ 0
Under previous revenue guidance | ASU 2014-09              
Disaggregation of revenue              
Revenue     67,802,000        
Development revenue              
Disaggregation of revenue              
Revenue     20,391,000 $ 37,833,000 $ 14,198,000    
License revenue              
Disaggregation of revenue              
Revenue     $ 39,114,000        
License revenue | NY-ESO program              
Change in contract with customer, liability              
Revenue recognized in the period   $ 39,114,000          
Revenue recognized included in contract liability at beginning of the period $ 27,001,000            
GlaxoSmithKline Intellectual Property Development Ltd              
Contract assets, liability and receivables              
Number of customers     1 1   1  
Number of geographic locations | item     1